Long-term prediction of clinical outcomes by the 21-gene test in HR+HER2-breast cancer patients with residual disease after neoadjuvant chemotherapy

Peg, V.de los Angeles, N.Vieites, B.Bellet, M.Castilla, C.Gomez Pardo, P.Perez-Luque, A.Lopez, M. A.Salvador Bofill, F. J.Alfaro, L.Perez Garcia, J. M.Espinosa-Bravo, M.2023-05-032023-05-032022-05-050923-7534http://hdl.handle.net/10668/21903enLong-term prediction of clinical outcomes by the 21-gene test in HR+HER2-breast cancer patients with residual disease after neoadjuvant chemotherapyconference outputopen access10.1016/j.annonc.2022.03.1181569-8041http://www.annalsofoncology.org/article/S0923753422004975/pdf792494100104